This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of urethral disorders: A Synthesis of Findings from 101 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of urethral disorders: A Synthesis of Findings from 101 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main research findings

The research findings primarily focus on the treatment of ulcerative colitis (UC), a chronic inflammatory bowel disease. While aminosalicylates are widely used for UC maintenance treatment, 13 reveals that patients continue to experience bothersome symptoms, often at night. Although medical advancements in UC treatment have improved, approximately 25-40% of patients require surgical intervention during their disease, according to 51 . Elective surgical treatment for UC aims to remove the colon and rectum with minimal post-operative complications, aiming for a good quality of life in the long run. The most common surgical procedure currently offered is restorative proctocolectomy and ileal pouch-anal anastomosis. 80 suggests that probiotics, like bifid triple viable (BTV), can potentially reduce adverse reactions caused by aminosalicylic acid (ASA) while demonstrating a positive clinical effect on UC. On the other hand, 22 highlights the effectiveness of topical butyrate in treating distal ulcerative colitis, which is often resistant to traditional 5-ASA/steroid treatment. The study aimed to validate prior research indicating the usefulness of this approach.

Treatment summary

The studies highlight various treatments for UC, ranging from conventional medications like aminosalicylates ( 13 , 80 , 22 ) to more recent approaches such as probiotics ( 80 , 83 ), fecal microbiota transplantation ( 85 ), and biological therapies like TNF inhibitors (). The effectiveness of 67 methotrexate in inducing steroid-free remission in UC patients with steroid-dependent disease is also explored.

Benefits and Risks

Benefit Summary

These studies suggest a multitude of treatment options for UC, aiming to improve patient quality of life. 65 discusses the impact of surgical treatment on quality of life after total proctocolectomy with ileostomy or IPAA. 95 examines the prevalence of aphthous stomatitis in IBD patients after treatment with monoclonal antibodies. 88 explores the potential effectiveness of acupuncture in treating UC. The studies also suggest that probiotics, topical butyrate application, new biological therapies, and acupuncture can be beneficial for patients.

Risk Summary

The treatment of UC can come with side effects. Medication treatment, such as mesalazine and steroids, can lead to adverse reactions like nausea, vomiting, diarrhea, and rashes. Newer therapies, such as biological agents, fecal microbiota transplantation, and methotrexate, may pose risks like infections.

Research Comparisons

Research Commonalities

These studies share the common goal of investigating treatments for UC. Many of them focus on improving patient quality of life.

Research Differences

The studies differ in their target populations, treatment modalities, and research designs. For instance, 13 compares balsalazide and mesalazine for UC remission maintenance, while 80 explores the effectiveness of probiotic and ASA combination therapy. 95 delves into the impact of monoclonal antibodies on aphthous stomatitis. These research studies approach UC treatment from diverse angles.

Consistency and Inconsistencies of Results

While the research showcases various options for treating UC, a definitive conclusion regarding the most effective treatment remains elusive. Additionally, treatment effectiveness varies among individuals, emphasizing the importance of personalized treatment approaches.

Applying Findings to Real Life: Considerations

Treatment for UC should always be under the guidance of a medical professional. Not all treatments discussed in these studies are suitable for every individual. Consultation with a doctor is crucial to determine the most appropriate treatment based on personal symptoms and conditions.

Limitations of Current Research

The research conducted in these studies involved limited sample sizes, necessitating larger-scale studies for more definitive results. The complexity of UC, involving multiple contributing factors, necessitates caution when generalizing research findings to all individuals.

Future Research Directions

Future research efforts should focus on larger-scale studies with larger patient cohorts to establish more robust treatment effectiveness. Additionally, a deeper understanding of UC's pathogenesis is crucial for developing more effective treatment modalities.

Conclusion

The studies illustrate significant advancements in UC treatment in recent times. However, challenges remain, requiring continued research and development. If you are dealing with UC, consult a healthcare professional for proper diagnosis and treatment tailored to your individual needs.

Treatment List

Aminosalicylates, balsalazide, mesalazine, butyrate, probiotics, bifid triple viable, TNF inhibitors, vedolizumab, acupuncture, fecal microbiota transplantation, VSL#3, methotrexate, infliximab, corticosteroids, diosmectite, biological therapies, ciprofloxacin, transdermal nicotine, levamisole, sulfasalazine, phosphatidylcholine, curcumin.


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 101 papers
Positive Content
94
Neutral Content
1
Negative Content
6
Article Type
52
31
43
26
101

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: IngramJohn R, ThomasGareth A O, RhodesJohn, GreenJohn T, HawkesNeil D, SwiftJill L, SrivastavaEmmanuel D, EvansBrian K, WilliamsGeraint T, NewcombeRobert G, CourtneyEdward, PillaiSuresh


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Language : English


Language : Spanish


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: CarbonnelFranck, ColombelJean Frédéric, FilippiJérome, KatsanosKonstantinos H, Peyrin-BirouletLaurent, AllezMathieu, NachuryMaria, NovacekGottfried, DaneseSilvio, AbitbolVered, BossaFabrizio, MoreauJacques, BommelaerGilles, BourreilleArnaud, FumeryMathurin, RoblinXavier, ReinischWalter, BouhnikYoram, BrixiHedia, SeksikPhilippe, MalamutGeorgia, FärkkiläMartti, CoulibalyBaya, DewitOlivier, LouisEdouard, DeplanqueDominique, MichettiPierre, SarterHélène, LaharieDavid,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Spanish


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.